Printer Friendly

Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder.

Activating somatic point mutations in exons 7, 10, and 15 of the FGFR3 gene are frequently observed in urothelial cell carcinoma (UCC) (1,2). These mutations have been found primarily in superficial papillary pTa tumors and were absent in carcinoma in situ (3).

Given the high frequency of FGFR3 mutations and the possible implication of this receptor in the development of UCC, it was important to develop a simple, fast, and reliable method to identify these mutations in greater detail as a potential tool for the diagnosis and follow-up of UCC patients.

Ten different FGFR3 mutations have been described in UCC, but 4 of them (R248C, S249C, G372C, and Y375C) account for >95% of cases (2). These mutations therefore represent an excellent target for assays, such as allele-specific PCR (AS-PCR), that depend on the specific detection of point mutations.

The general principle underlying the AS-PCR technique is to design a mutation-specific primer that produces the preferential amplification of a specific mutant allele (4). We compared the results obtained with this assay with those obtained by direct sequencing in a series of 95 DNA samples extracted from UCC tumors. We also analyzed matching tumors and voided urine from 20 patients. Our results demonstrate the sensitivity, specificity, and reliability of this technique for detecting FGFR3 mutations in both tumors and urine from patients with UCC.

Ninety-five primary tumor samples were collected from patients admitted to the Department of Urology of Hospitals Henri Mondor (Creteil) and CHRU (Besancon) and who had received no previous treatment. Patients gave written informed consent, and we collected matched tumors and blood samples. Tumors from each patient were snap-frozen and stored at -80[degrees]C. DNA from tumor samples was extracted as described previously (5). DNA was extracted from the blood with use of the QIAamp system (Qiagen S.A.).

An additional 20 formalin-fixed, paraffin-embedded tumors were studied. In some of these tumors, the tumoral tissue was manually microdissected under a microscope to remove regions of healthy mucosa. DNA was extracted from paraffin-embedded tissues by use of the DNeasy[R] Tissue reagent set (Qiagen).

Tumors were graded according to the WHO classification of 1973 (6), and stage was determined according to the 1997 TNM classification guidelines (7).

In these 20 cases, samples of voided urine (25-100 mL) collected at the time of diagnosis were tested in parallel with their matching tumor samples. Freshly voided urine samples were stored at 4[degrees]C. The urine samples were centrifuged within 12 h after being voided, and cell pellets were stored at -20[degrees]C until the DNA was extracted (usually within 1 week). DNA was extracted from urinary cells by use of the Qiagen DNA extraction reagent set.

The DNA concentration was measured fluorometrically with Picogreen quantification reagents (Bioprobes; Interchim).

PCRs were carried out in an Eppendorf thermocycler (Mastercycle; VWR). PCR was performed in a final volume of 25 /,L containing 5 ng of genomic DNA, 1 x PCR buffer (Perkin-Elmer Taq polymerase buffer), 200 [mu]M each of the deoxynucleoside triphosphate, 2.5 mM Mg[Cl.sub.2] for PCR1 or 2 mM Mg[Cl.sub.2] for PCR 2, 2.5 [micro]L of dimethyl sulfoxide, 2.5 U of gold Taq polymerase (Perkin-Elmer), and primers at the concentrations indicated in Table 1 of the Data Supplement that accompanies the online version of this Technical Brief at Cycling conditions were as follows: 95[degrees]C for 5 min followed by 35 cycles of 95[degrees]C for 15 s, 61[degrees]C for 15 s, and 72[degrees]C for 15 s.

We used DNA samples from tumors harboring 4 known FGFR3 mutations (R248C, S249C, G372C, and Y375C) to set up the PCR conditions so that only mutated DNA and not wild-type DNA was amplified in 2 different PCRs: PCR1 for detection of the R248C and G372C mutations, and PCR2 for S249C and Y375C. In both PCRs, a pair of primers amplifying a fragment of the [beta]-globin gene was included as an internal control. For each primer pair, a fluorescent primer was used to label the PCR product. All primers were obtained from Applied Biosystems.

We explored the effect of various conditions on AS-PCR amplification: for each AS-PCR, 3 mutation-specific oligonucleotides differing from each other by the position and type of mismatch were tested at the same concentration in a solution containing 2.5 mM [Mg.sup.2+]. The allele-specific primers that we tested all matched the mutated sequence at their 3' extremity (i.e., mismatched the wild-type sequence), and contained 1 or 2 additional mismatches vs both the wild-type and mutated sequences. For each mutation, the oligonucleotide that yielded the greatest specificity compatible with efficient PCR was selected. The final PCR conditions to be used were chosen from 3 concentrations of AS oligonucleotide and 3 concentrations of [Mg.sup.2+] with a fixed annealing temperature. The conditions giving the best amplification of mutated DNA with complete specificity are shown in Table 1 of the online Data Supplement.

PCR products were analyzed on an ABI PRISM 310 capillary DNA sequencer with the Genscan software.

Mutated DNA was diluted in wild-type DNA to determine the sensitivity of each mutation-specific PCR: in every case, 0.2 ng of mutated DNA mixed with 4.8 ng of wild-type DNA (1:25 dilution) yielded a detectable signal (Fig. 1). The ratio of each mutation-specific signal to that corresponding to [beta]-globin was calculated and used as a threshold to determine whether an unknown DNA sample was to be classified as positive or negative (Fig. 1 of the online Data Supplement).

We checked the validity of our assay by use of a series of 95 DNA samples extracted from UCC tumors that had been studied by directly sequencing exons 7, 10, and 15 of the FGFR3 gene. The following mutations were found by sequencing: S249C (23 samples), Y375C (9 samples), R248C (3 samples), K652E (2 samples), K652M (1 sample), G372C (3 sample), S373C (1 sample), and G382R (1 sample). When we used sequencing as the comparison method, AS-PCR had a specificity of 90% and a sensitivity of 88% (Table 1). Five mutations found by sequencing were not looked for by AS-PCR. In 5 cases in which no mutation had been found by sequencing, AS-PCR did detect mutations (1 sample with the R248C mutation, 3 with the S249C mutation, and 1 with the Y375C mutation). It is likely that in these latter cases AS-PCR was able to detect a mutation present only in a small fraction of the cells and that could not therefore be easily be detected by sequencing. This hypothesis is supported by the dilution experiments mentioned above.

Using the same technique (AS-PCR), we tested 20 paired samples from patients with UCC for whom both a tumor sample and DNA extracted from urinary cells at the time of diagnosis were available. Ten pairs of samples had an FGFR3 mutation (1 with R248C, 6 with S249C, 2 with S373C, and 1 with Y375C), and the other 10 pairs had no detectable mutation. Matched tumors and urine from the same patient gave exactly the same results. Mutations found according to stage and grade of tumors are shown in Table 2 of the online Data Supplement.


The PCR assay we developed permits the accurate detection of the 4 most common ([approximately equal to] 95% of mutated cases) FGFR3 mutations found in UCC. This assay is based on the specific amplification of mutated DNA. In a recent report, van Rhijn et al. (8) detected FGFR3 mutations in only 11 of 21 urine samples from patients whose tumor contained an FGFR3 mutation. The lower sensitivity of detection reported in that study by single-strand conformation polymorphism analysis of PCR products was thought to result from a dilution effect caused by the presence of healthy cells in the urine. Although our present data need to be confirmed in larger series, these preliminary findings support the idea that FGFR3 mutations can be detected with high sensitivity in urinary cells when a mutation is present in the matching tumor. Our test seems to be suitable for future routine clinical practice. In particular, the use of a sensitive PCR test instead of repeated cystoscopy is likely to have important potential clinical implications for the follow-up of patients with a FGFR3 mutation in the initial tumor. However, because our study was carried out on primary tumors rather on recurrent tumors, which are usually smaller, a prospective study of the diagnostic value of this test for the detection of recurrences should be undertaken.

Because FGFR3 mutations occur at a high frequency in low-grade tumors, our test complements other available tests to provide early, noninvasive detection of bladder cancer. Indeed, these tests, such as morphologic cytology or microsatellite analysis of the urine, are more sensitive for high-grade than for low-grade tumors (8-10).

This research was funded by INSERM, Universite Paris 12 and Paris 7, Association de la Recherche Contre le Cancer (ARC), Delegation a la recherche Clinique, Assistance Publique Hopitaux de Paris (AP-HP), Program Hospitalier de Recherche Clinique (AOA 94015 and AOM 03115), and Ligue Nationale Contre Le Cancer. We acknowledge the skillful technical work of Aurelie Brice.


(1.) Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.

(2.) van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. EurJ Hum Genet 2002;10:819-24.

(3.) Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9.

(4.) Bottema CD, Sommer SS. PCR amplification of specific alleles: rapid detection of known mutations and polymorphisms. Mutat Res 1993;288: 93-102.

(5.) Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997;14:3059-66.

(6.) Mostofi F Sobin L, Torloni H, eds. Histological typing of urinary bladder tumors. International histological classification of tumors, No. 10. Geneva: WHO, 1973.

(7.) Sobin LH, Fleming LID. TNM classification of malignant tumors, 5th ed., Vol. 80. Philadelphia: Union Internationale Contre le Cancer and the American Joint Committee on Cancer, 1997:1803-4.

(8.) van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003;9:257-63.

(9.) Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80.

(10.) Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, et al. Identification of fbroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98:737-44.

DOI : 10.1373/clinchem.2005.049619

Ashraf A. Bakkar, [1] Viviane Quach, [2] Anaig Le Borgne, [2] Marianne Toublanc, [3] Dominique Henin, [3] Herve Wallerand, [5] Francois Radvanyi, [4] Hugues Bittard, [5] Vincent Ravery, [6] Laurent Boccon Gibod, [6] Sixtina Gil Diez de Medina, [1] Dominique K. Chopin, [1] and Bernard Grandchamp [2] *

([1] EMI INSERM 03-37 and Service d'Urologie, Universite Paris 12, AP-HP, Hopital Henri Mondor, Creteil, France; [2] Service de Biochimie et Genetique, [3] Service d'Anatomie et Cytologie Pathologiques, and [6] Service d'Urologie, Universite Paris 7, AP-HP, IFR02, Hopital Bichat-Claude Bernard, Paris, France; [4] UMR 144, CNRS Institut Curie, Paris, France; [5] Service d'Urologie CHRU Besancon, France; * address correspondence to this author at: Service de Biochimie et Genetique, Hopital Bichat, 46 rue Henri Huchard 75018 Paris, France)
Table 1. FGFR3 mutations detected by sequencing
and AS-PCR.

 Mutation-positive by Mutation-negative by
 sequencing, n sequencing, n

AS-PCR+ 38 5
AS-PCR- 5 (a) 48

(a) These mutations correspond to K652E (2 cases), S373C (1 case),
G382R (1 case), and K652M (1 case). In 1 patient, 2 mutations
(G382R and S249C) were found by sequencing, whereas only the
S249C was looked for and found by AS-PCR.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technical Briefs
Author:Bakkar, Ashraf A.; Quach, Viviane; Le Borgne, Anaig; Toublanc, Marianne; Henin, Dominique; Wallerand
Publication:Clinical Chemistry
Date:Aug 1, 2005
Previous Article:Homocysteine stability in heparinized plasma stored in a gel separator tube.
Next Article:Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice.

Related Articles
Multiplexed assays for detection of mutations in PIK3CA.
Biochip for K-ras mutation screening in ovarian cancer.
Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-line mutation in Spanish patients with hematologic malignancies.
Detection of p53 polymorphism at codon 72 by PCR and allele-specific oligonucleotide hybridization on microtiter plates.
BRCAI gene mutations in sporadic ovarian carcinomas: Detection by PCR and reverse allele-specific oligonucleotide hybridization.
K-ras mutation detection by hybridization to a polypyrrole DNA chip.
Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction...
Detection of h-ras mutations in urine sediments by a mutant-enriched PCR technique.
Denaturing gradient gel electrophoresis-based analysis of loss of heterozygosity distinguishes nonobvious, deleterious BRCA1 variants from...
Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA I by PCR-mediated site-directed mutagenesis.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters